BZ019 / Shanghai Cell Therapy Group - LARVOL DELTA

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Unknown status ➔ Completed

Trial completion • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • BCL6

Study of Efficacy of BZ019 in Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Shanghai Mengchao Cancer Hospital

New P2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • IL10 • IL2 • IL6

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Institute of Hematology & Blood Diseases Hospital; Recruiting ➔ Active, not recruiting; N=30 ➔ 12; Trial primary completion date: Dec 2019 ➔ Jul 2020

Clinical • Enrollment change • Enrollment closed • Trial primary completion date • BCL2

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma (clinicaltrials.gov) - P1; N=21; Recruiting; Sponsor: Shanghai Cell Therapy Group Co.,Ltd

Clinical • New P1 trial